Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Abstract

Purpose: Restrictive clinical trial eligibility criteria (EC) limit the number of patients who can enroll and potentially benefit from protocol-driven, investigational treatment plans and reduce the generalizability of trial results to the broader population. Following publication of expert stakeholder recommendations for broadening EC in 2017, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) convened working groups to produce additional recommendations and analyze the potential impact on clinical trials using real-world data. Experimental Design: Multistakeholder working groups were appointed by an ASCO-Friends leadership group to propose recommendations for more inclusive EC related to: washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and performance status. Results: The four working groups, ASCO Board of Directors, and Friends leadership support the recommendations included in this statement to modernize EC related to washout periods, concomitant medications, prior therapies, laboratory references ranges and test intervals, and performance status to make trial populations more inclusive and representative of cancer patient populations. Conclusions: Implementation of the recommendations is intended to result in greater ease of determining patient eligibility. Increased opportunities for patient participation in research will help address longstanding underrepresentation of certain groups in clinical trials and produce evidence that is more informative for a broader patient population. More patients eligible will also likely speed clinical trial accrual. See related commentary by Giantonio, p. 2369

Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes

“…Access to clinical trials can be improved by eliminating unnecessarily restrictive clinical trial eligibility criteria, such as the ongoing collaboration between ASCO, Friends of Cancer Research, and the U.S. Food and Drug Administration to modernize clinical trial eligibility criteria. [136][137][138][139][140][141][142] Wide adoption of these criteria will make it more feasible to promote attainment of specific targets for opening clinical access to underserved populations that can be set forth by the pharmaceutical industry, contract research organizations, the U.S. Food and Drug Administration, and the National Cancer Institute.…”

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

“…4 Collaborations with the American Association for Cancer Research, American Society of Clinical Oncology and Friends of Cancer Research are also ongoing in other areas such as performance status, prior therapy, drug washout period, and laboratory abnormalities. [21][22][23][24][25] These efforts hope to result in a more complete picture of drug effect in populations not typically included in clinical trials, as well as support the enrollment of more ethnic and racially diverse populations.…”

Gender profile of principal investigators in a large academic clinical trials group

“…The need to ensure balanced recruitment of patients for trials in all disciplines of medicine (and for that matter laboratory animals for pre-clinical research) has given rise to the Sex and Gender Equity in Research (SAGER) guidelines, amongst others ( 33 – 35 ). The phenomenon of female under-representation as clinical trial PIs and academic leaders similarly cuts across all areas of medicine, surgery and medical research ( 36 – 38 ).…”